• J P Durand, G Deplanque, V Montheil, J M Gornet, F Scotte, O Mir, A Cessot, R Coriat, E Raymond, E Mitry, P Herait, Y Yataghene, and F Goldwasser.
• Department of Medical Oncology, Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Paris, France. jean-philippe.durand@cch.aphp.fr
• Ann. Oncol. 2012 Jan 1;23(1):200-5.

BackgroundOxaliplatin neurosensory toxicity is dose limiting and may present as acute symptoms and/or cumulative peripheral neuropathy.Patients And MethodsFrom October 2005 to May 2008, patients with oxaliplatin-induced acute neurotoxicity were randomized into a double-blind study, to receive either venlafaxine 50 mg 1 h prior oxaliplatin infusion and venlafaxine extended release 37.5 mg b.i.d. from day 2 to day 11 or placebo. Neurotoxicity was evaluated using numeric rating scale (NRS) for pain intensity and experienced relief under treatment, the Neuropathic Pain Symptom Inventory and the oxaliplatin-specific neurotoxicity scale. The primary end point was the percentage of patients with a 100% relief under treatment.ResultsForty-eight patients were included (27 males, median age: 67.6 years). Most patients had colorectal cancer (72.9%). Median number of cycles administered at inclusion was 4.5 (mean cumulative oxaliplatin dose: 684.6 mg). Twenty out of 24 patients in arm A (venlafaxine) and 22 out of 24 patients in arm B (placebo) were assessable for neurotoxicity. Based on the NRS, full relief was more frequent in the venlafaxine arm: 31.3% versus 5.3% (P=0.03). Venlafaxine side-effects included grade 1-2 nausea (43.1%) and asthenia (39.2%) without grade 3-4 events.ConclusionVenlafaxine has clinical activity against oxaliplatin-induced acute neurosensory toxicity.

21 keywords...

hide…